243 related articles for article (PubMed ID: 32665013)
1. Fyn depletion ameliorates tau
Liu G; Fiock KL; Levites Y; Golde TE; Hefti MM; Lee G
Acta Neuropathol Commun; 2020 Jul; 8(1):108. PubMed ID: 32665013
[TBL] [Abstract][Full Text] [Related]
2. Disease-related modifications in tau affect the interaction between Fyn and Tau.
Bhaskar K; Yen SH; Lee G
J Biol Chem; 2005 Oct; 280(42):35119-25. PubMed ID: 16115884
[TBL] [Abstract][Full Text] [Related]
3. Fyn Kinase Controls Tau Aggregation In Vivo.
Briner A; Götz J; Polanco JC
Cell Rep; 2020 Aug; 32(7):108045. PubMed ID: 32814048
[TBL] [Abstract][Full Text] [Related]
4. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines.
Xia D; Li C; Götz J
Biochim Biophys Acta; 2015 May; 1852(5):913-24. PubMed ID: 25558816
[TBL] [Abstract][Full Text] [Related]
5. Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Li C; Götz J
J Alzheimers Dis; 2018; 64(1):205-221. PubMed ID: 29782321
[TBL] [Abstract][Full Text] [Related]
6. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy.
Bhaskar K; Hobbs GA; Yen SH; Lee G
Neuropathol Appl Neurobiol; 2010 Oct; 36(6):462-77. PubMed ID: 20609109
[TBL] [Abstract][Full Text] [Related]
8. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
9. Neurotrophin receptor p75 mediates amyloid β-induced tau pathology.
Shen LL; Li WW; Xu YL; Gao SH; Xu MY; Bu XL; Liu YH; Wang J; Zhu J; Zeng F; Yao XQ; Gao CY; Xu ZQ; Zhou XF; Wang YJ
Neurobiol Dis; 2019 Dec; 132():104567. PubMed ID: 31394202
[TBL] [Abstract][Full Text] [Related]
10. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy.
Lim J; Balastik M; Lee TH; Nakamura K; Liou YC; Sun A; Finn G; Pastorino L; Lee VM; Lu KP
J Clin Invest; 2008 May; 118(5):1877-89. PubMed ID: 18431510
[TBL] [Abstract][Full Text] [Related]
11. Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines.
Padmanabhan P; Martínez-Mármol R; Xia D; Götz J; Meunier FA
Elife; 2019 Jun; 8():. PubMed ID: 31237563
[TBL] [Abstract][Full Text] [Related]
12. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P
Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380
[TBL] [Abstract][Full Text] [Related]
13. Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.
Reilly P; Winston CN; Baron KR; Trejo M; Rockenstein EM; Akers JC; Kfoury N; Diamond M; Masliah E; Rissman RA; Yuan SH
Neurobiol Dis; 2017 Oct; 106():222-234. PubMed ID: 28610892
[TBL] [Abstract][Full Text] [Related]
14. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
Helboe L; Egebjerg J; Barkholt P; Volbracht C
Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
[TBL] [Abstract][Full Text] [Related]
15. Sensory Neurons from Tau Transgenic Mice and Their Utility in Drug Screening.
Tolkovsky AM; Brelstaff J
Methods Mol Biol; 2018; 1727():93-105. PubMed ID: 29222775
[TBL] [Abstract][Full Text] [Related]
16. Picalm reduction exacerbates tau pathology in a murine tauopathy model.
Ando K; De Decker R; Vergara C; Yilmaz Z; Mansour S; Suain V; Sleegers K; de Fisenne MA; Houben S; Potier MC; Duyckaerts C; Watanabe T; Buée L; Leroy K; Brion JP
Acta Neuropathol; 2020 Apr; 139(4):773-789. PubMed ID: 31925534
[TBL] [Abstract][Full Text] [Related]
17. Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy.
Tang SJ; Fesharaki-Zadeh A; Takahashi H; Nies SH; Smith LM; Luo A; Chyung A; Chiasseu M; Strittmatter SM
Acta Neuropathol Commun; 2020 Jul; 8(1):96. PubMed ID: 32611392
[TBL] [Abstract][Full Text] [Related]
18. Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model.
Seino Y; Kawarabayashi T; Wakasaya Y; Watanabe M; Takamura A; Yamamoto-Watanabe Y; Kurata T; Abe K; Ikeda M; Westaway D; Murakami T; Hyslop PS; Matsubara E; Shoji M
J Neurosci Res; 2010 Dec; 88(16):3547-54. PubMed ID: 20936700
[TBL] [Abstract][Full Text] [Related]
19. Fyn, a potential target for Alzheimer's disease.
Yang K; Belrose J; Trepanier CH; Lei G; Jackson MF; MacDonald JF
J Alzheimers Dis; 2011; 27(2):243-52. PubMed ID: 21799250
[TBL] [Abstract][Full Text] [Related]
20. Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains.
Feuillette S; Deramecourt V; Laquerriere A; Duyckaerts C; Delisle MB; Maurage CA; Blum D; Buée L; Frébourg T; Campion D; Lecourtois M
Brain Res; 2010 Jul; 1345():182-9. PubMed ID: 20460118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
